Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Mar 15;6(3):e009942.
doi: 10.1136/bmjopen-2015-009942.

Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)

Daisuke Onozuka  1 , Akihito Hagihara  1 , Kunihiro Nishimura  2 , Akiko Kada  3 , Jyoji Nakagawara  4 , Kuniaki Ogasawara  5 , Junichi Ono  6 , Yoshiaki Shiokawa  7 , Toru Aruga  8 , Shigeru Miyachi  9 , Izumi Nagata  10 , Kazunori Toyoda  11 , Shinya Matsuda  12 , Akifumi Suzuki  13 , Hiroharu Kataoka  14 , Fumiaki Nakamura  15 , Satoru Kamitani  15 , Ataru Nishimura  16 , Ryota Kurogi  16 , Tetsuro Sayama  16 , Koji Iihara  16 ; J-ASPECT Study Collaborators
Affiliations
Observational Study

Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)

Daisuke Onozuka et al. BMJ Open. .

Abstract

Objectives: To elucidate the association between antiplatelet use in patients with non-haemorrhagic moyamoya disease before hospital admission and good functional status on admission in Japan.

Design: Retrospective, multicentre, non-randomised, observational study.

Setting: Nationwide registry data in Japan.

Participants: A total of 1925 patients with non-haemorrhagic moyamoya disease admitted between 1 April 2012 and 31 March 2014 in Japan.

Main outcome measure: We performed propensity score-matched analysis to examine the association between prehospital antiplatelet use and no significant disability on hospital admission, as defined by a modified Rankin Scale score of 0 or 1.

Results: Propensity-matched patients who received prehospital antiplatelet drugs were associated with a good outcome on hospital admission (OR adjusted for all covariates, 3.82; 95% CI 1.22 to 11.99) compared with those who did not receive antiplatelet drugs prior to hospital admission.

Conclusions: Prehospital antiplatelet use was significantly associated with good functional status on hospital admission among patients with non-haemorrhagic moyamoya disease in Japan. Our results suggest that prehospital antiplatelet use should be considered when evaluating outcomes of patients with non-haemorrhagic moyamoya disease.

Keywords: EPIDEMIOLOGY; STATISTICS & RESEARCH METHODS; STROKE MEDICINE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study participant selection.
See this image and copyright information in PMC

References

    1. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol 2008;7:1056–66. 10.1016/S1474-4422(08)70240-0 - DOI - PubMed
    1. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009;360:1226–37. 10.1056/NEJMra0804622 - DOI - PubMed
    1. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012;52:245–66. - PubMed
    1. Suzuki J, Kodama N. Moyamoya disease—a review. Stroke 1983;14:104–9. - PubMed
    1. Caldarelli M, Di Rocco C, Gaglini P. Surgical treatment of moyamoya disease in pediatric age. J Neurosurg Sci 2001;45:83–91. - PubMed

Publication types

Substances